Orangekloud Technology Inc. (ORKT)
NASDAQ: ORKT · Real-Time Price · USD
0.7750
+0.0454 (6.22%)
Aug 6, 2025, 4:00 PM - Market closed
Augmedix Stock Forecast
ORKT's stock price has decreased by -84.89% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Augmedix stock has a target of 5.00, which predicts a 545.16% increase from the current stock price of 0.78.
Price Target: $5.00 (+545.16%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 30, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Augmedix is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 |
|---|---|---|
| Strong Buy | 1 | 1 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
| Total | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy Initiates $5 | Strong Buy | Initiates | $5 | +545.16% | Jan 30, 2025 |
Financial Forecast
Revenue This Year
4.43M
from 4.04M
Increased by 9.63%
Revenue Next Year
n/a
from 4.43M
EPS This Year
-0.04
from -0.40
EPS Next Year
n/a
from -0.04
Financial currency is SGD. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 |
|---|---|
| High | 4.6M |
| Avg | 4.4M |
| Low | 4.3M |
Revenue Growth
| Revenue Growth | 2026 |
|---|---|
| High | 12.8% |
| Avg | 9.6% |
| Low | 5.3% |
EPS Forecast
| EPS | 2026 |
|---|---|
| High | -0.04 |
| Avg | -0.04 |
| Low | -0.04 |
EPS Growth
| EPS Growth | 2026 |
|---|---|
| High | - |
| Avg | - |
| Low | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.